Patent ID: 6074643
Filing Date: 2000-06-13
Classification: A61K,A61P,C07K,C12N,C12Q,G01N,Y10S

Abstract:
A method of site-directed chemotherapy of metastatic cells of non-lymphoid tumor origin, wherein the metastatic cells are in a state selected from the group consisting of a dormant state, and a pseudo-resting state, said site-directed chemotherapy is directed to prometastatic territories of a target organ having or suspected of having arrested metastatic cells, and said method comprises concentrating in the prometastatic territories by introducing directly into a vascular access of the organ:(a) a therapeutically effective amount of a component selected from the group consisting of IL-2, and IL-1, to activate pseudo-resting or dormant metastatic cells; and(b) a chemotherapeutic agent comprised of a targeting molecule linked to an antitumor agent, wherein the targeting molecule has binding specificity for a cell-surface molecule preferentially expressed by type 1 endothelial cells as compared to expression by type 2 endothelial cells in the prometastatic territories, and wherein the antitumor agent is a therapeutically effective amount of an agent active against proliferating cells which contacts and effects death of proliferating metastatic cells if present in the prometastatic territories.